Melanosis and prolactin (bromocriptine)

Authors

  • Juan Coyotupa Instituto de Investigaciones de la Altura, Universidad Peruana Cayetano Heredia, Lima, Perú
  • Carolina Santa María Hospital Municipal Dr. Teodoro Alvarez, Buenos Aires, Argentina
  • Abraham Guitelman Hospital Municipal Dr. Teodoro Alvarez, Buenos Aires, Argentina

DOI:

https://doi.org/10.31403/rpgo.v39i1349

Abstract

This paper is a prospective evaluation of 59 patients with facial melanosis treatment they received as bromocriptine 5 mg / day for 6 months. After treatment of 51 patients improved and in 9 patients Melanosis melanosis persisted. In this study group 38 patients with hyperprolactinemia and after six months was found in 7 patients and 31 Hyperprolactinaemia persisted and were Normoprolactenemicas. Also in the group of 30 patients they had Galactorrea Melanosis and the end of treatment only 1 patient still had Galactorrea, while the remaining 37 were no longer Galactorrea. The fact that a dopamine fix on the one hand and on the other Melanosis hyperprolactinemia and galactorrhea, indicating that secretion of prolactin and alpha-MSH is under inhibitory control by dopamine would be the PIF and physiological MIF.

Downloads

Download data is not yet available.

Published

2015-07-14

How to Cite

Coyotupa, J., Santa María, C., & Guitelman, A. (2015). Melanosis and prolactin (bromocriptine). The Peruvian Journal of Gynecology and Obstetrics, 39(14), 24–29. https://doi.org/10.31403/rpgo.v39i1349

Issue

Section

Artículos Originales